Novartis AG
DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
Last updated:
Abstract:
S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
Status:
Application
Type:
Utility
Filling date:
10 Jan 2020
Issue date:
16 Jul 2020